The QbD Group acquires Michor Consulting to enhance its regulatory affairs services across Europe
The QbD Group, a privately held company offering comprehensive support to life science companies throughout the entire product lifecycle, today announced the acquisition of Michor Consulting. Michor Consulting offers services related to regulatory affairs and compliance, business organization, and quality assurance.
Since 2008, Michor has been providing consulting services covering the full range of regulatory affairs needs from strategy and submissions to technical writing and software selection. Founder and CEO Dr. Salma Michor is the incoming Chair of the Regulatory Affairs Professionals Society European office (RAPS Europe). In addition, the team are experts in Chinese regulations and provide support to companies that are looking to become active on the Chinese market.
QbD will be adding Michor’s quality expertise to their Regulatory Affairs division, which offers advice and support for traditional pharmaceutical products, vaccines, biologicals, medical devices, and Advanced Therapy Medicinal Products (ATMP) to name a few areas. With this new acquisition, the QbD Group can also strengthen its services for regulatory affairs in the DACH (Germany (D), Austria (A), and Switzerland (CH)) region where Michor is actively operating. The combined knowledge of QbD and Michor will give clients the benefit of over a decade of experience.
Dr. Salma Michor, founder and CEO of Michor Consulting said: “I am excited to join QbD Group’s Regulatory Affairs division. The experience we have built up at Michor will perfectly complement the knowledge at QbD and we are looking forward to having the opportunity to enhance our skills together. By joining the QbD group we will be able to take on larger projects and complement our services to offer clients a complete solution in life sciences.”
"QbD Group is pleased to be adding Michor's regulatory experts to our already robust team. Regulatory affairs are a crucial step in medical device, pharmaceutical, and biotech advancements. With the additional expertise in combination products, we continue to extend the range of support that we can provide to our clients.” - Bart Van Acker, Founder and CEO of QbD Group
